Skip to Main content
Number of documents

9

Didier Blaise


Journal articles9 documents

  • Raynier Devillier, Anne‐sophie Chrétien, Thomas Pagliardini, Nassim Salem, Didier Blaise, et al.. Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. Journal of Leukocyte Biology, Society for Leukocyte Biology, 2021, 109 (6), pp.1071-1088. ⟨10.1002/JLB.5MR0920-198RR⟩. ⟨hal-03623194⟩
  • Annalisa Ruggeri, Myriam Labopin, Andrea Bacigalupo, Boris Afanasyev, Jan J Cornelissen, et al.. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. Journal of Hematology and Oncology, BioMed Central, 2018, 11, pp.40. ⟨10.1186/s13045-018-0586-4⟩. ⟨hal-01762520⟩
  • Anne-Sophie Chrétien, Raynier Devillier, Cyril Fauriat, Florence Orlanducci, Samia Harbi, et al.. NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. OncoImmunology, Taylor & Francis, 2017, 6 (12), pp.e1307491. ⟨10.1080/2162402X.2017.1307491⟩. ⟨hal-01789566⟩
  • Florent Malard, Myriam Labopin, Ibrahim Yakoub-Agha, Sylvain Chantepie, Thierry Guillaume, et al.. Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. Blood, American Society of Hematology, 2017, 130 (20), pp.2186-2195. ⟨10.1182/blood-2017-05-786137⟩. ⟨inserm-02155352⟩
  • Frédéric Baron, Annalisa Ruggeri, Eric Beohou, Myriam Labopin, Mohamad Mohty, et al.. Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. Journal of Hematology and Oncology, BioMed Central, 2016, 10 (1), pp.128. ⟨10.1186/s13045-017-0497-9⟩. ⟨inserm-01546618⟩
  • Patrice Chevallier, Marie Labopin, Régis Peffault de La Tour, Bruno Lioure, Claude-Eric Bulabois, et al.. Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS. Cancer Medicine, Wiley, 2016, 5 (11), pp.3068 - 3076. ⟨10.1002/cam4.880⟩. ⟨hal-01818593⟩
  • Marie Thérèse Rubio, Maud D’aveni-Piney, Myriam Labopin, Rose-Marie Hamladji, Miguel A. Sanz, et al.. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party. Journal of Hematology and Oncology, BioMed Central, 2016, 10 (1), pp.31. ⟨10.1186/s13045-016-0389-4⟩. ⟨inserm-01444368⟩
  • Didier Blaise, Raynier Devillier, Anne-Gaelle Lecoroller-Sorriano, Jean-Marie Boher, Agnès Boyer-Chammard, et al.. Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. Haematologica, Ferrata Storti Foundation, 2015, 100 (2), pp.269-274. ⟨10.3324/haematol.2014.113571⟩. ⟨hal-02167058⟩
  • Christel Protière, G, Tonnaire, Didier Blaise, Dominique Maraninchi, Moatti Jean-Paul. Evaluation économétrique du coût d'une allogreffe de moelle osseuse. Journal d'Economie Médicale, Masson, 1996, 14 (6), pp.323-331. ⟨inserm-03199671⟩